CONMED (NYSE:CNMD) Posts Earnings Results, Beats Expectations By $0.11 EPS

CONMED (NYSE:CNMD) issued its quarterly earnings results on Wednesday. The company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.32 by $0.11, FiscalAI reports. CONMED had a net margin of 4.75% and a return on equity of 14.22%.

Here are the key takeaways from CONMED’s conference call:

• CONMED reported Q4 sales of $373.2M (+7.1% cc) and full‑year sales of $1.375B, with Q4 adjusted EPS of $1.43 (+6.7%) and FY adjusted EPS of $4.59 (+10.1%), reflecting solid top‑line and adjusted profitability growth.
• Management announced the December exit of its gastroenterology product lines, which will cause near‑term earnings dilution but is expected to improve long‑term consolidated growth margins by about 80 basis points once complete.
• Supply‑chain remediation in sports medicine showed material progress — backorder value and SKUs on backorder hit a three‑year low — enabling the sales force to be more proactive and supporting orthopedic growth momentum.
• Key growth platforms showed traction: AirSeal (~1.6M procedures in 2025 and large laparoscopy white space), Buffalo Filter with the new PlumeSafe X5 and legislative tailwinds, and BioBrace adoption plus an ongoing RCT expected to finish enrollment in 2026.
• 2026 guidance reflects mixed headwinds — revenue guide of $1.345–$1.375B (organic cc +4.5–6%) and adjusted EPS of $4.30–$4.45 (below 2025 adjusted EPS) with ~$0.45–0.50 EPS impact from the GI exit and ~$0.30–0.35 from incremental tariffs, even as the board suspended the dividend and approved a $150M buyback.

CONMED Stock Down 2.5%

CNMD traded down $0.99 on Wednesday, reaching $38.59. The company’s stock had a trading volume of 668,073 shares, compared to its average volume of 606,648. The stock has a 50 day moving average of $41.53 and a two-hundred day moving average of $46.55. CONMED has a fifty-two week low of $38.32 and a fifty-two week high of $74.70. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 18.83, a P/E/G ratio of 1.84 and a beta of 0.96.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CNMD. Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. Wells Fargo & Company reduced their price target on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 6th. Piper Sandler dropped their price objective on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Bank of America cut their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Finally, Zacks Research lowered shares of CONMED from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $53.67.

Institutional Investors Weigh In On CONMED

Several large investors have recently modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new position in CONMED during the 3rd quarter valued at about $488,000. Danske Bank A S purchased a new position in shares of CONMED during the 3rd quarter worth about $546,000. Wasatch Advisors LP acquired a new position in shares of CONMED in the 3rd quarter valued at $47,026,000. Sherbrooke Park Advisers LLC purchased a new stake in CONMED during the third quarter valued at about $211,000. Finally, Quarry LP increased its position in CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after purchasing an additional 617 shares in the last quarter.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.